KalVista Pharmaceuticals
Dec 16, 2024 · KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista’s mission begins with hereditary angioedema, HAE. Patients & Caregivers
KalVista Announces Orphan Drug Designation and NDA …
1 day ago · CAMBRIDGE, Mass. & SALISBURY, England, January 21, 2025--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted ...
About Us - KalVista Pharmaceuticals
KalVista Pharmaceuticals is a biopharmaceutical company discovering, developing and commercializing oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system.
KALV Stock Price | KalVista Pharmaceuticals Inc. Stock Quote …
6 days ago · KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases...
KalVista Pharmaceuticals, Inc. (KALV) Stock Price, News, Quote ...
Find the latest KalVista Pharmaceuticals, Inc. (KALV) stock quote, history, news and other vital information to help you with your stock trading and investing.
Pipeline - KalVista Pharmaceuticals
KalVista is building a pipeline of novel oral, small molecule protease inhibitors through preclinical and clinical development as potential best-in-class treatments for a range of diseases, beginning with hereditary angioedema (HAE).
KalVista Pharmaceuticals, Inc. (KALV) - Stock Analysis
5 days ago · Get a real-time KalVista Pharmaceuticals, Inc. (KALV) stock price quote with breaking news, financials, statistics, charts and more.
KalVista Announces FDA Acceptance of New Drug Application for ...
Sep 3, 2024 · KalVista announced positive phase 3 data from the KONFIDENT trial for its oral, on-demand therapy, sebetralstat for HAE in February 2024. The Company’s NDA for sebetralstat has been accepted by the FDA with a PDUFA goal date of June 17, 2025 .
KalVista Pharmaceuticals Provides Operational Update and Fiscal …
Apr 30, 2024 · KalVista Pharmaceuticals, Inc. is a global pharmaceutical company focused on the development and delivery of oral medicines for diseases with significant unmet need. KalVista announced positive phase 3 data for the KONFIDENT trial for its oral, on-demand therapy sebetralstat in February 2024 and submitted an NDA with the FDA in June 2024 .
Kalvista Pharmaceuticals Inc (KALV) Stock Price & News - Google
Get the latest Kalvista Pharmaceuticals Inc (KALV) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...